{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T19:20:46Z","timestamp":1780082446020,"version":"3.54.0"},"reference-count":37,"publisher":"Bentham Science Publishers Ltd.","issue":"6","funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico, CNPq","doi-asserted-by":"publisher","award":["306530\/2020-1"],"award-info":[{"award-number":["306530\/2020-1"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior, CAPES","doi-asserted-by":"publisher","award":["88882.385863\/2019- 01"],"award-info":[{"award-number":["88882.385863\/2019- 01"]}],"id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNSNDDT"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Pharmacological treatments for mental disorders, such as anxiety and depression,\npresent several limitations and adverse effects. Therefore, new pharmacotherapy with\nanxiolytic and antidepressant potential is necessary, and the study of compounds capable of interacting\nwith more than one pharmacological target may provide new therapeutic options.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>In this study, we proposed the design, synthesis of a new compound, 2-(4-((1-\nphenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)ethyl acetate (LQFM192), pharmacological evaluation\nof its anxiolytic-like and antidepressant-like activities, as well as the possible mechanisms of\naction involved.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Administration of LQFM192 was carried out prior to the exposure of male Swiss mice to\nbehavioral tests, such as the elevated plus-maze and forced swimming test. The involvement of the\nserotonergic system was studied by pretreatment with WAY-100635 or p-chlorophenylalanine (PCPA)\nand the involvement of the benzodiazepine site of the GABAA receptor by pretreatment with\nflumazenil.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>The treatment with LQFM192 at doses of 54 and 162 \u03bcmol\/kg demonstrated anxiolyticlike\nactivity that was blocked by WAY-100635, PCPA, and flumazenil pretreatments. The potential\nantidepressant-like activity was visualized at the same doses and blocked by WAY-100635 and\nPCPA.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>In summary, the anxiolytic-like activity of LQFM192 is mediated by the serotonergic\nsystem and the benzodiazepine site of the GABAA receptor, and the antidepressant-like activity\nthrough the serotonergic system.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1871527320666211112173233","type":"journal-article","created":{"date-parts":[[2021,11,12]],"date-time":"2021-11-12T13:46:27Z","timestamp":1636724787000},"page":"520-532","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Neuropharmacological Activity of the New Piperazine Derivative 2-(4-((1-\nPhenyl-1H-Pyrazol-4-yl)Methyl)Piperazin-1-yl)Ethyl Acetate is Modulated\nby Serotonergic and GABAergic Pathways"],"prefix":"10.2174","volume":"21","author":[{"given":"Elson Alves","family":"Costa","sequence":"first","affiliation":[{"name":"Laboratory of Pharmacology of Natural and Synthetic Products, Institute of Biological Sciences, Federal University\nof Goi\u00e1s, Goi\u00e2nia, GO, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena de Souza","family":"Almeida","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology of Natural and Synthetic Products, Institute of Biological Sciences, Federal University\nof Goi\u00e1s, Goi\u00e2nia, GO, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ianca Gontijo Cavalcante","family":"Santana","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology of Natural and Synthetic Products, Institute of Biological Sciences, Federal University\nof Goi\u00e1s, Goi\u00e2nia, GO, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorrane Kelle","family":"da Silva Moreira","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology of Natural and Synthetic Products, Institute of Biological Sciences, Federal University\nof Goi\u00e1s, Goi\u00e2nia, GO, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa C\u00f3rdova","family":"Turones","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology of Natural and Synthetic Products, Institute of Biological Sciences, Federal University\nof Goi\u00e1s, Goi\u00e2nia, GO, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germ\u00e1n","family":"Sanz","sequence":"additional","affiliation":[{"name":"Chemistry Institute, Laboratory of Chromatography and Mass Spectrometry, Federal University of Goi\u00e1s, Goi\u00e2nia,\nGO, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boniek G.","family":"Vaz","sequence":"additional","affiliation":[{"name":"Chemistry Institute, Laboratory of Chromatography and Mass Spectrometry, Federal University of Goi\u00e1s, Goi\u00e2nia,\nGO, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fl\u00e1vio S.","family":"de Carvalho","sequence":"additional","affiliation":[{"name":"Laboratory\nof Medicinal Pharmaceutical Chemistry, Faculty of Pharmacy, Federal University of Goi\u00e1s, Goi\u00e2nia, GO, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano M.","family":"Li\u00e3o","sequence":"additional","affiliation":[{"name":"Chemistry Institute, Federal University of Goi\u00e1s, Campus Samambaia, Goi\u00e2nia, GO, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Menegatti","sequence":"additional","affiliation":[{"name":"Laboratory\nof Medicinal Pharmaceutical Chemistry, Faculty of Pharmacy, Federal University of Goi\u00e1s, Goi\u00e2nia, GO, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriane Ferreira","family":"de Brito","sequence":"additional","affiliation":[{"name":"Laboratory of Pharmacology of Natural and Synthetic Products, Institute of Biological Sciences, Federal University\nof Goi\u00e1s, Goi\u00e2nia, GO, Brazil"},{"name":"Paulista University, Campus Goi\u00e2nia Flamboyant, Goi\u00e2nia, GO, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","year":"2014","unstructured":"APA - American Psychiatric Association. Diagnostic and statistical manual of mental disorders. (5th ed.), Arlington, VA: American Psychiatric Publishing 2014"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1590\/S1415-790X2010000400008","volume":"13","author":"Rocha S.V.","year":"2010","unstructured":"Rocha S.V.; de Almeida M.M.; de Ara\u00fajo T.M.; Virtuoso J.S.; Prevalence of common mental disorders among the residents of urban areas in Feira de Santana, Bahia. Rev Bras Epidemiol 2010,13(4),630-640","journal-title":"Rev Bras Epidemiol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/ajmg.c.30172","volume":"148C","author":"Mathew S.J.","year":"2008","unstructured":"Mathew S.J.; Price R.B.; Charney D.S.; Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics. Am J Med Genet C Semin Med Genet 2008,148C(2),89-98","journal-title":"Am J Med Genet C Semin Med Genet"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.psc.2009.05.004","volume":"32","author":"Martin E.I.","year":"2009","unstructured":"Martin E.I.; Ressler K.J.; Binder E.; Nemeroff C.B.; The neurobiology of anxiety disorders: brain imaging, genetics, and psychoneuroendocrinology. Psychiatr Clin North Am 2009,32(3),549-575","journal-title":"Psychiatr Clin North Am"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"S109","DOI":"10.1016\/j.euroneuro.2006.04.003","volume":"16","author":"Nutt D.","year":"2006","unstructured":"Nutt D.; Argyropoulos S.; Hood S.; Potokar J.; Generalized anxiety disorder: A comorbid disease. Eur Neuropsychopharmacol 2006,16(Suppl. 2),S109-S118","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.cellsig.2004.12.007","volume":"17","author":"Taylor C.","year":"2005","unstructured":"Taylor C.; Fricker A.D.; Devi L.A.; Gomes I.; Mechanisms of action of antidepressants: from neurotransmitter systems to signaling pathways. Cell Signal 2005,17(5),549-557","journal-title":"Cell Signal"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.31887\/DCNS.2017.19.2\/bbandelow","volume":"19","author":"Bandelow B.","year":"2017","unstructured":"Bandelow B.; Michaelis S.; Wedekind D.; Treatment of anxiety disorders. Dialogues Clin Neurosci 2017,19(2),93-107","journal-title":"Dialogues Clin Neurosci"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1590\/S1516-44461999000500006","volume":"21","author":"Moreno R.A.","year":"1999","unstructured":"Moreno R.A.; Moreno D.H.; Soares M.B.M.; Psicofarmacologia de antidepressivos. Rev Bras Psiquiatr 1999,21,24-40","journal-title":"Rev Bras Psiquiatr"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/fcp.12408","volume":"33","author":"Brito A.F.","year":"2019","unstructured":"Brito A.F.; Moreira L.K.S.; Menegatti R.; Costa E.A.; Piperazine derivatives with central pharmacological activity used as therapeutic tools. Fundam Clin Pharmacol 2019,33(1),13-24","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/cbdd.12961","volume":"90","author":"Brito A.F.","year":"2017","unstructured":"Brito A.F.; Fajemiroye J.O.; Neri H.F.S.; Silva D.M.; Silva D.P.B.; Sanz G.; Vaz B.G.; de Carvalho F.S.; Ghedini P.C.; Li\u00e3o L.M.; Menegatti R.; Costa E.A.; Anxiolytic-like effect of 2-(4-((1-phenyl-1H-pyrazol-4-yl)methyl)piperazin-1-yl)ethan-1-ol is mediated through the benzodiazepine and nicotinic pathways. Chem Biol Drug Des 2017,90(3),432-442","journal-title":"Chem Biol Drug Des"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.neuropharm.2007.06.028","volume":"53","author":"Sood A.","year":"2007","unstructured":"Sood A.; Warren Beach J.; Webster S.J.; Terry A.V.; Buccafusco J.J.; The effects of JWB1-84-1 on memory-related task performance by amyloid Abeta transgenic mice and by young and aged monkeys. Neuropharmacology 2007,53(5),588-600","journal-title":"Neuropharmacology"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1007\/BF00177912","volume":"92","author":"Lister R.G.","year":"1987","unstructured":"Lister R.G.; The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 1987,92(2),180-185","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/0165-0270(85)90031-7","volume":"14","author":"Pellow S.","year":"1985","unstructured":"Pellow S.; Chopin P.; File S.E.; Briley M.; Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985,14(3),149-167","journal-title":"J Neurosci Methods"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1038\/266730a0","volume":"266","author":"Porsolt R.D.","year":"1977","unstructured":"Porsolt R.D.; Le Pichon M.; Jalfre M.; Depression: a new animal model sensitive to antidepressant treatments. Nature 1977,266(5604),730-732","journal-title":"Nature"},{"key":"ref=15","doi-asserted-by":"publisher","DOI":"10.1039\/jr9570003024","volume":"3024-3027","author":"Finar I.","year":"1957","unstructured":"Finar I.; Hurlock R.; The preparation of some trinitrophenylpyrazoles. J Chem Soc 1957,3024-3027","journal-title":"J Chem Soc"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1080\/00397911.2012.657764","volume":"43","author":"De Oliveira C.H.A.","year":"2013","unstructured":"De Oliveira C.H.A.; Mairink L.M.; Pazini F.; Li\u00e3o L.M.; De Oliveira A.L.; Viegas J.R.; De Oliveira V.; Cunha L.C.; Oliveira F.G.F.; Paz J.L.; Eberlin M.N.; Menegatti R.; Chemoselective and regiospecific formylation of 1-phenyl-1H-pyrazoles through the Duff reaction. Synth Commun 2013,43,1633-1639","journal-title":"Synth Commun"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.1016\/j.bmcl.2004.10.005","volume":"14","author":"Luo G.","year":"2004","unstructured":"Luo G.; Mattson G.K.; Bruce M.A.; Wong H.; Murphy B.J.; Longhi D.; Antal-Zimanyi I.; Poindexter G.S.; Isosteric N-arylpiperazine replacements in a series of dihydropyridine NPY receptor antagonists. Bioorg Med Chem Lett 2004,14(24),5975-5978","journal-title":"Bioorg Med Chem Lett"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"954","DOI":"10.3390\/catal3040954","volume":"3","author":"Lugemwa F.N.","year":"2013","unstructured":"Lugemwa F.N.; Shaikh K.; Hochstedt E.; Facile and efficient acetylation of primary alcohols and phenols with acetic anhydride catalyzed by dried sodium bicarbonate. Catalysts 2013,3(4),954-965","journal-title":"Catalysts"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1080\/13543776.2016.1189902","volume":"26","author":"Rathi A.K.","year":"2016","unstructured":"Rathi A.K.; Syed R.; Shin H.S.; Patel R.V.; Piperazine derivatives for therapeutic use: a patent review (2010-present). Expert Opin Ther Pat 2016,26(7),777-797","journal-title":"Expert Opin Ther Pat"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.lfs.2015.11.009","volume":"143","author":"Galdino P.M.","year":"2015","unstructured":"Galdino P.M.; de Oliveira D.R.; Florentino I.F.; Fajemiroye J.O.; Valadares M.C.; de Moura S.S.; da Rocha F.F.; de Lima T.C.; Costa E.A.; Menegatti R.; Involvement of the monoamine system in antidepressant-like properties of 4-(1-phenyl-1h-pyrazol-4-ylmethyl)-piperazine-1-carboxylic acid ethyl ester. Life Sci 2015,143,187-193","journal-title":"Life Sci"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/S0166-4328(01)00291-1","volume":"125","author":"Belzung C.","year":"2001","unstructured":"Belzung C.; Griebel G.; Measuring normal and pathological anxiety-like behaviour in mice: A review. Behav Brain Res 2001,125(1-2),141-149","journal-title":"Behav Brain Res"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00213-008-1378-2","volume":"203","author":"Roy V.","year":"2009","unstructured":"Roy V.; Chapillon P.; Jeljeli M.; Caston J.; Belzung C.; Free versus forced exposure to an elevated plus-maze: evidence for new behavioral interpretations during test and retest. Psychopharmacology (Berl) 2009,203(1),131-141","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/j.neubiorev.2005.04.017","volume":"29","author":"Carobrez A.P.","year":"2005","unstructured":"Carobrez A.P.; Bertoglio L.J.; Ethological and temporal analyses of anxiety-like behavior: the elevated plus-maze model 20 years on. Neurosci Biobehav Rev 2005,29(8),1193-1205","journal-title":"Neurosci Biobehav Rev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1472-8206.2007.00526.x","volume":"21","author":"Bourin M.","year":"2007","unstructured":"Bourin M.; Petit-Demouli\u00e8re B.; Dhonnchadha B.N.; Hasc\u00f6et M.; Animal models of anxiety in mice. Fundam Clin Pharmacol 2007,21(6),567-574","journal-title":"Fundam Clin Pharmacol"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0091-3057(96)00402-9","volume":"57","author":"Griebel G.","year":"1997","unstructured":"Griebel G.; Rodgers R.J.; Perrault G.; Sanger D.J.; Risk assessment behaviour: evaluation of utility in the study of 5-HT-related drugs in the rat elevated plus-maze test. Pharmacol Biochem Behav 1997,57(4),817-827","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2147\/NDT.S58841","volume":"11","author":"Nuss P.","year":"2015","unstructured":"Nuss P.; Anxiety disorders and GABA neurotransmission: A disturbance of modulation. Neuropsychiatr Dis Treat 2015,11,165-175","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2174\/157015906776359540","volume":"4","author":"Ciranna L.","year":"2006","unstructured":"Ciranna L.; Serotonin as a modulator of glutamate- and GABA-mediated neurotransmission: implications in physiological functions and in pathology. Curr Neuropharmacol 2006,4(2),101-114","journal-title":"Curr Neuropharmacol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/0197-0186(85)90172-X","volume":"7","author":"Didier M.","year":"1985","unstructured":"Didier M.; Belin M.F.; Aguera M.; Buda M.; Pujol J.F.; Pharmacological effects of GABA on serotonin metabolism in the rat brain. Neurochem Int 1985,7(3),481-489","journal-title":"Neurochem Int"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.lfs.2018.08.050","volume":"210","author":"&#x17B;mudzka E.","year":"2018","unstructured":"&#x17B;mudzka E.; Sa\u0142aciak K.; Sapa J.; Pytka K.; Serotonin receptors in depression and anxiety: Insights from animal studies. Life Sci 2018,210,106-124","journal-title":"Life Sci"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/0091-3057(95)02135-3","volume":"54","author":"Graeff F.G.","year":"1996","unstructured":"Graeff F.G.; Guimar\u00e3es F.S.; De Andrade T.G.; Deakin J.F.; Role of 5-HT in stress, anxiety, and depression. Pharmacol Biochem Behav 1996,54(1),129-141","journal-title":"Pharmacol Biochem Behav"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s00213-007-0728-9","volume":"192","author":"O\u2019Leary O.F.","year":"2007","unstructured":"O\u2019Leary O.F.; Bechtholt A.J.; Crowley J.J.; Hill T.E.; Page M.E.; Lucki I.; Depletion of serotonin and catecholamines block the acute behavioral response to different classes of antidepressant drugs in the mouse tail suspension test. Psychopharmacology (Berl) 2007,192(3),357-371","journal-title":"Psychopharmacology (Berl)"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.5498\/wjp.v5.i4.366","volume":"5","author":"Coplan J.D.","year":"2015","unstructured":"Coplan J.D.; Aaronson C.J.; Panthangi V.; Kim Y.; Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches. World J Psychiatry 2015,5(4),366-378","journal-title":"World J Psychiatry"},{"key":"ref=33","year":"2017","unstructured":"World Health Organization Depression and Other Common Mental Disorders: Global Health Estimates World Health Organization, Ginebra 2017","journal-title":"World Health Organization Depression and Other Common Mental Disorders: Global Health Estimates World Health Organization, Ginebra"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1016\/j.physbeh.2013.05.012","volume":"118","author":"Bogdanova O.V.","year":"2013","unstructured":"Bogdanova O.V.; Kanekar S.; D\u2019Anci K.E.; Renshaw P.F.; Factors influencing behavior in the forced swim test. Physiol Behav 2013,118,227-239","journal-title":"Physiol Behav"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1038\/nn.2647","volume":"13","author":"Nestler E.J.","year":"2010","unstructured":"Nestler E.J.; Hyman S.E.; Animal models of neuropsychiatric disorders. Nat Neurosci 2010,13(10),1161-1169","journal-title":"Nat Neurosci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"6503162","DOI":"10.1155\/2016\/6503162","volume":"2016","author":"de Kloet E.R.","year":"2016","unstructured":"de Kloet E.R.; Molendijk M.L.; Coping with the Forced Swim Stressor: Towards Understanding an Adaptive Mechanism. Neural Plast 2016,2016,6503162","journal-title":"Neural Plast"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1002\/wps.20229","volume":"14","author":"Cowen P.J.","year":"2015","unstructured":"Cowen P.J.; Browning M.; What has serotonin to do with depression? World Psychiatry 2015,14(2),158-160","journal-title":"World Psychiatry"}],"container-title":["CNS &amp; Neurological Disorders - Drug Targets"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527320666211112173233","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/197924\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1871527320666211112173233","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,8]],"date-time":"2022-11-08T15:57:03Z","timestamp":1667923023000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/197924\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":37,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1871527320666211112173233","relation":{},"ISSN":["1871-5273"],"issn-type":[{"value":"1871-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-08-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}